Compare IRWD & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | STXS |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.8M | 210.0M |
| IPO Year | 2010 | 2004 |
| Metric | IRWD | STXS |
|---|---|---|
| Price | $3.55 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $5.34 | $4.00 |
| AVG Volume (30 Days) | ★ 2.3M | 471.4K |
| Earning Date | 11-10-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $338,987,000.00 | $30,075,000.00 |
| Revenue This Year | N/A | $24.48 |
| Revenue Next Year | $4.01 | $29.98 |
| P/E Ratio | $20.22 | ★ N/A |
| Revenue Growth | N/A | ★ 19.62 |
| 52 Week Low | $0.53 | $1.54 |
| 52 Week High | $5.13 | $3.59 |
| Indicator | IRWD | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 44.44 |
| Support Level | $3.50 | $2.34 |
| Resistance Level | $3.80 | $2.44 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 55.49 | 55.17 |
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.